Difficult-to-treat rheumatoid arthritis. What is it?
https://doi.org/10.14412/1996-7012-2021-5-7-11
Abstract
The widespread introduction into clinical practice of modern approaches to the treatment of rheumatoid arthritis (RA), the rational use of traditional and targeted antirheumatic drugs can effectively suppress inflammatory activity, restrain the progression of the disease and improve the quality of life of patients. At the same time, in some patients, even after the repeated change of targeted drugs, it is not possible to achieve the target level of RA activity. Serious difficulties arising in the management of such patients raised the question of identifying a special variant of the disease – difficult-to-treat (D2T) RA. The presence of various variants of D2T RA and the need to use a personalized approach to therapy justify the creation of special recommendations for the management of this category of patients. The first step in preparing these recommendations was the definition of D2T RA recently presented by the EULAR working group. It includes three criteria: 1) insufficient effectiveness of the therapy; 2) the presence of an active symptomatic disease; 3) clinical perception.
About the Authors
A. V. Gordeev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Andrey Viktorovich Gordeev
134A, Kashirskoe Shosse, Moscow 115522
Yu. A. Olyunin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
134A, Kashirskoe Shosse, Moscow 115522
E. A. Galushko
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
134A, Kashirskoe Shosse, Moscow 115522
E. G. Zotkin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
134A, Kashirskoe Shosse, Moscow 115522
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; 34A, Kashirskoe Shosse, Moscow 115522, Russia; 22/1
Russian Federation
Russian Federation
134A, Kashirskoe Shosse, Moscow 115522
Barrikadnaya Street, Build. 1, Moscow 125993
References
1. Gabriel SE, Crowson CS. Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis. UpToDate April 2019. https://www.uptodate.com/contents/epidemiology-of-risk-factors-for-and-possiblecauses-of-rheumatoid-arthritis.
2. Saraux A, Guedes C, Allain J, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J Rheumatol. 1999 Dec;26(12):2622-7.
3. Balabanova RM, Dubinina TV, Demina AB, Krichevskaya OA. The incidence of diseases of the musculoskeletal system in the Russian Federation for 2015-2016. Nauchno-prakticheskaya revmatologiya. 2018;56(1):15-21. (In Russ.).
4. Nasonov EL. Pharmacotherapy of rheumatoid arthritis: russian and international recommendations. Nauchno-prakticheskaya revmatologiya. 2016;54(5):557-71. (In Russ.).
5. Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-5. doi: 10.1136/annrheumdis-2020-217344
6. Olyunin YuA. Assessment of pain in rheumatoid arthritis. Practical significance. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(1):121-8. (In Russ.). doi: 10.14412/1996-7012-2019-1-121-128
7. Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: problems of remission and resistance to therapy. Nauchno-prakticheskaya revmatologiya. 2018;56(3):263-71. (In Russ.).
8. Ferreira RJO, Duarte C, Ndosi M, et al. Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. Arthritis Care Res (Hoboken). 2018 Mar;70(3):369-78. doi: 10.1002/acr.23284
9. Studenic P, Smolen JS, Aletaha D. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis. 2012 Oct;71(10):1702-5. doi: 10.1136/annrheumdis-2012-201519
10. Lila AM, Olyunin YuA, Gordeev AV. Assessing the status of patients with rheumatoid arthritis: modern tendencies. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(2):7-13. (In Russ.). doi: 10.14412/1996-7012-2020-2-7-13
11. Lee YC, Frits ML, Iannaccone CK, et al. Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors. Arthritis Rheumatol. 2014 Aug;66(8):2006-14. doi: 10.1002/art.38682.
12. Emery P, Horton S, Dumitru RB, et al. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Ann Rheum Dis. 2020 Apr;79(4):464-71. doi: 10.1136/annrheumdis-2019-216539.
13. Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Res Ther. 2017 Mar 23;19(1):68. doi: 10.1186/s13075-017-1266-4.
14. Firestein GS. The disease formerly known as rheumatoid arthritis. Arthritis Res Ther. 2014;16(3):114. doi: 10.1186/ar4593.
15. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992 Nov 15;117(10):801-6. doi: 10.7326/0003-4819-117-10-801.
16. Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis. 2012 Jun;71(6):989-92. doi: 10.1136/annrheumdis-2011-201066.
17. Nemtsova MV, Zaletaev DV, Bure IV, et al. Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis. Front Genet. 2019 Jun 14;10:570. doi: 10.3389/fgene.2019.00570.
18. Nair N, Plant D, Verstappen SM, et al; MATURA investigators. Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology (Oxford). 2020 Jun 1;59(6):1364-71. doi: 10.1093/rheumatology/kez411.
19. Alivernini S, Kurowska-Stolarska M, Tolusso B, et al. MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nat Commun. 2016 Sep 27;7:12970. doi: 10.1038/ncomms12970.
20. Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol. 2013 Feb 1;190(3):1297-303. doi: 10.4049/jimmunol.1202572.
21. Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat Biotechnol. 2013 Feb;31(2):142-7. doi: 10.1038/nbt.2487.
22. Savola P, Kelkka T, Rajala HL, et al. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat Commun. 2017 Jun 21;8:15869. doi: 10.1038/ncomms15869.
23. Meng W, Zhu Z, Jiang X, et al. DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis. Arthritis Res Ther. 2017 Mar 29;19(1): 71. doi: 10.1186/s13075-017-1276-2.
24. Bendayan R, Cooper R, Muthuri SG. Lifetime cigarette smoking and chronic widespread and regional pain in later adulthood: evidence from the 1946 British birth cohort study. BMJ Open. 2018 Aug 29;8(8):e021896. doi: 10.1136/bmjopen-2018-021896.
25. Wiesenfeld-Hallin Z. Sex differences in pain perception. Gend Med. 2005 Sep;2(3): 137-45. doi: 10.1016/s1550-8579(05)80042-7.
26. Becede M, Alasti F, Gessl I, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019 Oct;49(2):211-7. doi: 10.1016/j.semarthrit.2019.02.004.
27. Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016 Dec 3;338:114-29. doi: 10.1016/j.neuroscience.2016.06.006.
28. Schrepf A, Kaplan CM, Ichesco E, et al. A multi-modal MRI study of the central response to inflammation in rheumatoid arthritis. Nat Commun. 2018 Jun 8;9(1):2243. doi: 10.1038/s41467-018-04648-0.
29. Abramkin AA, Lisitsyna TA, Vel'tishchev DYu, et al. Factors affecting the effectiveness of therapy in patients with rheumatoid arthritis: the role of comorbid mental and somatic pathology. Nauchno-prakticheskaya revmatologiya. 2018;56(4):439-48. (In Russ.).
30. Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014 Jan;73(1):62-8. doi: 10.1136/annrheumdis-2013-204223.
31. Lila AM, Gordeev AV, Olyunin YuA, Galushko EA. Multimorbidity in rheumatology. From comprehensive assessment of disease to evaluation of a set of diseases. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(3):4-9. (In Russ.). doi: 10.14412/1996-7012-2019-3-4-9
32. Rybakova VV, Olyunin YuA, Likhacheva EV, Nasonov EL. Indicators of rheumatoid arthritis disease activity. An association with a patient’s psychological status. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(2):27-34. (In Russ.). doi: 10.14412/1996-7012-2020-2-27-34
33. Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-35. doi: 10.1136/annrheumdis-2020-217344.
34. Buch MH. Defining refractory rheumatoid arthritis. Ann Rheum Dis 2018;77:966-9. doi:10.1136/annrheumdis-2017-212862
Review
For citations:
Gordeev AV, Olyunin YA, Galushko EA, Zotkin EG, Lila AM. Difficult-to-treat rheumatoid arthritis. What is it? Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(5):7-11. https://doi.org/10.14412/1996-7012-2021-5-7-11
Views:
1072
Email this article 